We are in the news this week! ✨ Proxima is proud to feature alongside our friends at Tessara Therapeutics, Pacalis Therapeutics Pty Ltd, Immunosis, Nutromics and Misti in Forbes Australia. There’s plenty of innovative science happening at Jumar Bioincubator and we are so excited to see the Melbourne biotech ecosystem grow! 🌱 https://lnkd.in/gTueKAZ6 #biotech #startups #innovation #biotechnology #biotechaustralia
About us
Proxima Bio is a venture-backed biotechnology company developing the next generation of medicines, cell surface degraders. Their technology provides new opportunities to target previously undruggable, disease-causing proteins, with powerful potential applications in autoimmune conditions and cancers.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Proxima Bio
-
Hamish McWilliam
Principal Scientist @ Proxima Bio /// Senior Research Fellow @ The Doherty Institute, The University of Melbourne /// Lead Immunologist @ Misti
-
Dale Calleja
Scientist at Proxima Bio
-
Amanda Woon
COO at Proxima Bio | Venture Principal Scientist at WEHI Ventures | WOC in STEM Leadership Finalist
-
Arjun Balaji
Medical Doctor | Technology VC